Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
Portfolio Pulse from
Regeneron Pharmaceuticals announced promising results from the Phase 1/2 CHORD trial for their investigational gene therapy DB-OTO, showing significant hearing improvements in children with genetic hearing loss.
February 24, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals reported positive results from the CHORD trial for their gene therapy DB-OTO, showing significant hearing improvements in children with genetic hearing loss.
The positive trial results for DB-OTO are likely to boost investor confidence in Regeneron's pipeline, potentially leading to a short-term increase in stock price. The news is highly relevant as it directly pertains to Regeneron's product development and market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100